Radioimmunoscintigraphy (RIS) bectumomab (Tc99m贴上IMMU-LL2 Lymphoscan)评估复发性非霍奇金淋巴瘤(NHL)。

文章的细节

引用

复制到剪贴板

Lamonica D, Czuczman M, Nabi H, Klippenstein D,格罗斯曼Z

Radioimmunoscintigraphy (RIS) bectumomab (Tc99m贴上IMMU-LL2 Lymphoscan)评估复发性非霍奇金淋巴瘤(NHL)。

癌症Biother Radiopharm。2002年12月,17 (6):689 - 97。

PubMed ID

12537673 (在PubMed

]

文摘

的功效Tc99m-labeled anti-lymphoma抗体片段,bectumomab LymphoScan,分期的回顾性研究复发性或新诊断非霍奇金淋巴瘤(NHL)患者[7]和评估目标之前放射(RIT)[14]的病人。表现评分相对传统成像。肿瘤包括7低级、11的中档和3高档组织学亚型。计算x射线断层扫描,radiogallium成像、摄影和骨髓活检定义117个站点。Bectumomab透露这些网站的56%。4例bectumomab发现五个站点通过传统的成像不明显。此外,它在大脑中发现了一个网站,一个区域中未涉及的标准检查无症状的患者。Bectumomab成像通常失败的腹部和胸腔中部的位置,和擅长揭示疾病在头部和颈部。相对于柠檬酸Ga67成像,bectumomab是变量的性能,没有明确的解剖位置关系;有更好的定位和中间级NHL低。 Radiogallium out-performed bectumomab imaging in 23 sites, 19 of which were in patients with high or intermediate-grade disease. Bectumomab was superior to radiogallium at six sites, five of which involved low-grade tumor. CONCLUSION: Bectumomab shows promise as a pre-RIT probe for targeting of B-cell NHL. It excelled at defining small volume, low-grade disease. However, as a purely diagnostic agent, its performance was variable.

DrugBank数据引用了这篇文章

药物

Bectumomab